KDR and small cell lung carcinoma: Another Phase II study involving 24 S‐SCLC patients showed that the combination of apatinib (a VEGFR‐2 inhibitor) with first‐line chemotherapy extended both PFS (7.8 months vs. 4.9 months) and OS (12.1 months vs. 8.2 months) compared to chemotherapy alone [27].